Table 1.
Patient and treatment characteristics
| Clinical Factors | EGFR/ALK+ NSCLC BM Cohort (n = 91) | Wild Type Cohort (n = 257) | P |
|---|---|---|---|
| Age, y, median (range) | 60.0 (29.8,82.6) | 60.8 (37.3,92.8) | 0.059 |
| Sex n (%) | 0.57 | ||
| Male | 38 (42) | 117 (45) | |
| Female | 53 (58) | 142 (55) | |
| Smoking status n (%) | <0.001 | ||
| Smokers | 47 (52) | 233 (91) | |
| Nonsmokers | 44 (48) | 24 (9) | |
| KPS n (%) | 0.90 | ||
| <70 | 9 (10) | 28 (12) | |
| 70–80 | 35 (40) | 109 (46) | |
| >80 | 44 (50) | 99 (42) | |
| No. of brain metastases # median (range) and n (%) | 2.0 (1.00, ≥99$) | 2.0 (1.00, ≥99$) | 0.23 |
| 1 | 34 (37) | 118 (46) | |
| 2–3 | 24 (27) | 70 (28) | |
| >3 | 33 (36) | 66 (26) | |
| Extracranial metastases (ECM) n (%) | 0.04 | ||
| No | 26 (29) | 104 (41) | |
| Yes | 65 (71) | 152 (59) | |
| Clinical symptoms n (%) | 0.036 | ||
| Asymptomatic | 33 (37) | 68 (28) | |
| Symptomatic | 56 (63) | 178 (72) | |
| Synchronous n (%) | <0.001 | ||
| No | 39 (43) | 97 (38) | |
| Yes | 52 (57) | 160 (62) | |
| First-line treatment n (%) | |||
| SRS ± surgery | 30 (33) | 98 (39) | 0.48 |
| WBRT ± surgery | 39 (43) | 125 (50) | 0.40 |
| WBRT + SRS | 15 (17) | 16 (5) | 0.005 |
| Other | 7(7) | 18(6) | |
| TKI, target therapy n (%) | 0.0001 | ||
| Yes | 45 (33) | 0 (0.0) | |
| No | 91(67) | 257(100) | |
| Timing of targeted therapy n (%) | |||
| ALK+ (N = 23) | EGFR+ (N = 68) | ||
| Before BM diagnosis | 4 (17) | 11 (17) | |
| After BM diagnosis | 15 (65) | 48 (73) | |
| as first line | 7 (47) | 38 (79) | |
| at progression | 8 (53) | 10 (21) | |
| Both | 0 (0.0) | 6 (9) | |
| Never | 4 (17) | 1 (1) |
#Evaluated by MRI brain with gadolinium contrast.
$≥99 denote at least 99 brain metastases, which can be physically counted on MRI brain with contrast.